*MAR Gynecology and Urology (2025) 8:5*

*Case Report*

# Human Papillomavirus (HPV): A Decade of Prevention, Treatment, and Outcomes

Dr. Alvaro Peña Jiménez*

***Correspondence to:** Dr. Alvaro Peña Jiménez, Department of Gynecology and Obstetrics, Medical Centre American British Cowdray, Mexico City, Mexico.



Received: 26 May 2025

Published: 01 July 2025

***Abstract:***

*Human Papillomavirus (HPV) is one of the most prevalent sexually transmitted infections worldwide, with certain high-risk genotypes—particularly HPV types 16 and 18—being responsible for nearly all cases of cervical cancer and a significant proportion of oropharyngeal, vulvar, vaginal, penile, and anal cancers. Over the past decade, substantial progress has been achieved in the prevention and management of HPV-related diseases, largely due to the introduction and global dissemination of prophylactic HPV vaccines. However, despite the clear benefits, the uptake of HPV vaccination programs has been uneven across geographical and socioeconomic regions, often hindered by cultural stigma, misinformation, limited healthcare infrastructure, and affordability concerns. This article presents a comprehensive analysis of HPV's epidemiology, clinical manifestations, diagnostic protocols, treatment regimens, and preventive strategies, with a particular emphasis on the comparative outcomes of vaccinated and unvaccinated individuals. We also examine the global statistical trends over the past ten years (2015–2024), supported by clinical case studies, tabulated data, and graphical representations. Through this detailed review, we aim to reinforce the critical importance of early vaccination, routine screening, and multidisciplinary treatment in reducing HPV-related morbidity and mortality.*

## Introduction

Human Papillomavirus (HPV) represents a major public health challenge across the globe. As a group of more than 200 genetically distinct viruses, HPV is primarily transmitted through direct skin-to-skin or mucosal contact during sexual activity. While the majority of HPV infections are asymptomatic and self-limiting, persistent infection with high-risk oncogenic types—most notably HPV-16 and HPV-18—can lead to the development of malignant lesions, especially cervical intraepithelial neoplasia (CIN), which may progress to invasive cervical cancer if left untreated.

According to the World Health Organization (WHO), cervical cancer is the fourth most common cancer among women globally, with over 600,000 new cases and more than 340,000 deaths annually as of 2024. Nearly all of these cases are attributable to HPV infection. Beyond cervical cancer, HPV is also implicated in a growing

number of head and neck cancers, particularly oropharyngeal squamous cell carcinoma, which is increasingly prevalent among men.

The approval and widespread use of prophylactic HPV vaccines, such as Gardasil, Gardasil-9, and Cervarix, have marked a transformative milestone in the primary prevention of HPV-associated diseases. These vaccines have demonstrated high efficacy in preventing infection from the most virulent HPV genotypes and in reducing the incidence of high-grade precancerous lesions and genital warts, particularly when administered before the onset of sexual activity. Despite their proven effectiveness and favorable safety profile, global vaccine coverage remains suboptimal, especially in low- and middle-income countries, due to barriers related to vaccine access, cost, sociocultural factors, and public skepticism.

This article seeks to provide an in-depth examination of HPV from both clinical and public health perspectives. We analyze HPV-related disease progression, recent developments in diagnostic and therapeutic approaches, and the measurable impact of vaccination programs over the last ten years. Through the inclusion of real-world case studies, statistical analyses, and comparative outcomes, this review aims to highlight the urgent need for global collaboration to achieve the WHO's 2030 cervical cancer elimination strategy, which includes a target of 90% HPV vaccination coverage among girls by age 15.

Epidemiology and Transmission

- Transmission: Primarily through sexual contact.
- Incubation Period: Weeks to months.
- Peak Prevalence: Among individuals aged 15–25 years.

Global HPV Burden (2015–2024)

| Year | Estimated Global HPV Cases (in millions) | New Cervical Cancer Cases | HPV-Related Deaths |
|---|---|---|---|
| 2015 | 300 | 528,000 | 266,000 |
| 2017 | 315 | 550,000 | 275,000 |
| 2019 | 320 | 570,000 | 280,000 |
| 2021 | 330 | 580,000 | 282,000 |
| 2024 | 335 | 590,000 | 284,000 |

*Source: WHO, CDC, GLOBOCAN*

HPV Vaccines: Types and Coverage

Types of HPV Vaccines

| Vaccine Name | HPV Types Covered | Approved Age Group | Year Approved |
|---|---|---|---|
| Gardasil | 6, 11, 16, 18 | 9–26 years | 2006 |
| Gardasil-9 | 6, 11, 16, 18, 31, 33, 45, 52, 58 | 9–45 years | 2014 |
| Cervarix | 16, 18 | 9–25 years | 2007 |

Global Vaccination Coverage (2015–2024)

*Figure 1: Increasing vaccine coverage globally. Higher coverage in high-income countries.*

| Region | Coverage in 2015 | Coverage in 2024 |
|---|---|---|
| North America | 65% | 78% |
| Europe | 55% | 70% |
| Sub-Saharan Africa | 10% | 30% |
| Asia | 20% | 55% |
| Latin America | 45% | 65% |

**Case Report 1: Invasive Cervical Cancer in an Unvaccinated Woman**

A 34-year-old female from India presented to a gynecologic oncology clinic with complaints of persistent pelvic pain, irregular vaginal bleeding, postcoital spotting, and foul-smelling discharge for over four months. The patient had never received the HPV vaccine and reported having limited access to cervical cancer screening due to socioeconomic barriers. Her obstetric history revealed multiple full-term pregnancies and an early onset of sexual activity at 17 years of age. She had no history of smoking or immunosuppressive illness. On physical examination, a friable, ulcerated cervical lesion was identified, and a pelvic bimanual examination suggested parametrial involvement. A Pap smear revealed high-grade squamous intraepithelial lesions (HSIL), and subsequent colposcopic examination confirmed acetowhite changes and punctation indicative of advanced cervical dysplasia. Cervical biopsy confirmed cervical intraepithelial neoplasia grade III (CIN III), and polymerase chain reaction (PCR) testing for HPV genotyping revealed the presence of HPV type 16, a high-risk oncogenic strain responsible for the majority of cervical cancers worldwide (WHO, 2022).

Magnetic resonance imaging (MRI) of the pelvis showed a 4.1 cm cervical mass with infiltration into the parametrium, classifying the disease as FIGO stage IIB cervical cancer. Due to the advanced stage, the patient underwent a radical hysterectomy (Type III) with bilateral pelvic lymph node dissection, followed by adjuvant concurrent chemoradiation. She received external beam radiation therapy (50 Gy in 25 fractions) along with weekly cisplatin (40 mg/m²) for five weeks. Post-treatment assessments showed partial remission of the disease, and she is currently under regular follow-up every three months with no signs of metastasis, although experiencing some radiation-induced pelvic fibrosis.

This case exemplifies the severe outcome associated with unvaccinated individuals who contract high-risk HPV types. The progression from persistent HPV-16 infection to invasive cervical cancer in the absence of prophylactic vaccination and routine screening underscores the critical importance of primary prevention (Arbyn et al., 2020).

**Case Report 2: Spontaneous Regression of Mild Dysplasia in a Vaccinated Woman**

A 27-year-old woman from Australia, who had received the complete three-dose series of the Gardasil-9 HPV vaccine at age 13 through the national immunization program, presented for a routine cervical cancer screening. She had no gynecological complaints and was otherwise healthy. Her sexual history included a stable monogamous relationship, and she denied any history of sexually transmitted infections or tobacco use. During a routine Pap smear, the cytology revealed low-grade squamous intraepithelial lesions (LSIL). Reflex HPV DNA testing identified the presence of HPV type 52, a high-risk type included in the Gardasil-9 vaccine formulation. Colposcopic evaluation showed minimal acetowhite epithelium without vascular abnormalities. Cervical biopsy confirmed the presence of cervical intraepithelial neoplasia grade I (CIN I). Based on current guidelines, conservative management was initiated, given her vaccination status and the likelihood of immune-mediated clearance of the virus (Koshiol et al., 2008).

The patient was monitored with repeat cytology and HPV testing at 12 months, which showed complete resolution of the lesion and a negative HPV result. This spontaneous regression without medical or surgical intervention demonstrates the immune protection conferred by early HPV vaccination, which has been shown to reduce not only the incidence but also the persistence of HPV infections and their progression to high-grade lesions (Drolet et al., 2019).

This case emphasizes the value of prophylactic HPV vaccination in modifying the natural course of infection, even when breakthrough infections occur. The immune response primed by the vaccine facilitated viral clearance and lesion regression, preventing progression to more severe pathology.

Treatment Modalities

| Condition | Treatment | Success Rate (%) | Notes |
|---|---|---|---|
| Genital warts | Cryotherapy, Podophyllin, Imiquimod | 70–90% | Recurrence common |
| CIN I-II (precancerous) | LEEP, Cryosurgery, Laser ablation | 85–95% | Regular screening needed |
| Cervical cancer (early) | Hysterectomy, Radiation, Chemotherapy | 65–90% | Depends on stage |
| Oropharyngeal HPV Cancer | Chemoradiation, Surgery | 50–80% | HPV-positive have better prognosis |

HPV Vaccine Safety and Side Effects

Reported Side Effects

| Side Effect | Frequency (%) | Notes |
|---|---|---|
| Injection site pain | 80% | Mild and transient |
| Fever | 10% | Self-limiting |
| Fainting | 6% | Common in adolescents |
| Severe reactions | <0.01% | Rare anaphylaxis, no deaths |

Statistical Impact of HPV Vaccination (2014–2024)

| Metric | Pre-Vaccine (2014) | Post-Vaccine (2024) |
|---|---|---|
| HPV 16/18 Prevalence (age <25) | 22% | 2% |
| Genital Wart Incidence (age <20) | 4.5/1000 | 0.3/1000 |
| CIN III Cases | 120,000 | 45,000 |
| Cervical Cancer Mortality Rate | 7.5/100,000 | 4.2/100,000 |

## Discussion

Over the past decade, the global rollout of the human papillomavirus (HPV) vaccine has yielded measurable success in reducing the incidence of HPV infections and associated cervical diseases. Countries with high vaccination coverage, particularly among adolescent girls and increasingly among boys, have reported substantial declines in HPV-related genital warts, cervical intraepithelial neoplasia, and even early-stage cervical cancers (Drolet et al., 2019). For instance, in nations like Australia and the United Kingdom, where national immunization programs were adopted early and implemented comprehensively, studies have shown a decline of over 80% in vaccine-type HPV infections among vaccinated cohorts within ten years (Brisson et al., 2020). These improvements reinforce the long-term efficacy of vaccines such as Gardasil and Cervarix in providing type-specific immunity, especially against HPV types 16 and 18, which are responsible for approximately 70% of cervical cancer cases globally (WHO, 2022).

However, the benefits of vaccination are not uniformly distributed. Low- and middle-income countries (LMICs), where the burden of cervical cancer is disproportionately high, face significant challenges in implementing widespread HPV immunization programs. These include logistical barriers, limited funding, competing healthcare priorities, and sociocultural resistance to vaccination. Despite global initiatives such as Gavi's support for vaccine procurement, uptake in several regions of Sub-Saharan Africa, South Asia, and Latin America remains below 30% (Gavi, 2023). Additionally, vaccine misinformation, lack of adolescent health infrastructure, and missed opportunities in school-based delivery platforms further hinder coverage.

Affordability and access remain key challenges, especially for countries that lack the healthcare infrastructure to deliver multi-dose vaccines. Moreover, public awareness about HPV, its transmission, and its link to cervical cancer is still inadequate in many regions. In contrast to high-income settings, where regular screening programs (Pap smear, HPV DNA testing) and follow-up systems are standard, LMICs often lack systematic screening, leading to late-stage diagnoses and poorer outcomes. This disparity underscores the need for integrated public health strategies that not only provide vaccines but also ensure equitable access to cervical screening and treatment facilities.

To overcome these challenges, multifaceted interventions are required. These should include policy-level commitments to integrate HPV vaccination into national immunization schedules, investments in cold chain and delivery logistics, and education campaigns to dispel myths and increase vaccine acceptance. Newer developments, such as the possibility of a single-dose HPV vaccine schedule, offer hope for more feasible implementation in resource-limited settings and could significantly reduce costs and logistical burdens (WHO, 2022). The potential of herd immunity and community-wide protection further strengthens the case for comprehensive, gender-neutral vaccination programs.

## Conclusion

HPV continues to pose a formidable yet preventable threat to global public health. The last ten years have demonstrated that widespread and timely administration of HPV vaccines can lead to remarkable reductions in the incidence of precancerous lesions and HPV-related malignancies. Real-world evidence affirms that vaccination, especially when administered before the onset of sexual activity, significantly curtails the transmission of high-risk HPV strains and reduces the risk of developing cervical and other anogenital cancers. Despite these gains, challenges remain—particularly in ensuring that vaccine benefits reach all populations, regardless of socioeconomic status or geographic location. The World Health Organization's global strategy to eliminate cervical cancer as a public health problem by 2030 emphasizes three critical pillars: 90% of girls fully vaccinated by the age of 15, 70% of women screened at least twice in their lifetime, and 90% of women with cervical disease receiving appropriate treatment. Achieving these targets will require global cooperation, policy advocacy, resource mobilization, and community engagement.

Education is a cornerstone of this strategy. Empowering individuals, especially adolescents and their caregivers, with knowledge about HPV, its health consequences, and the protective role of vaccines can significantly improve uptake. Combined with accessible screening and robust healthcare systems, HPV vaccination holds the promise of transforming the landscape of women's health and eliminating cervical cancer for future generations.

## References

1. Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray, F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2), e191–e203. https://doi.org/10.1016/S2214-109X(19)30482-6

2. Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Afonso, J., ... & Jit, M. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet, 395(10224), 575–590. https://doi.org/10.1016/S0140-6736(20)30068-4

3. Drolet, M., Bénard, É., Pérez, N., Brisson, M., & HPV Vaccination Impact Study Group. (2019). Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. The Lancet, 394(10197), 497–509. https://doi.org/10.1016/S0140-6736(19)30298-3

4. Koshiol, J., Schroeder, J. C., Jamieson, D. J., Marshall, S. W., Duerr, A., Heilig, C. M., ... & Hildesheim, A. (2008). Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. American Journal of Epidemiology, 167(1), 137–144. https://doi.org/10.1093/aje/kwm268

5. World Health Organization. (2022). Human papillomavirus (HPV) and cervical cancer. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer

6. WHO Global HPV Surveillance Reports (2014–2024)

7. CDC HPV Statistics and Surveillance

8. GLOBOCAN Cancer Estimates 2023

9. Markowitz LE, et al. (2020). HPV vaccine effectiveness. The Lancet

10. Garland SM, et al. (2016). Safety of HPV vaccines: A systematic review. BMJ

.

**Medtronic**